Pfizer's Sutent for liver cancer - FAIL
OSI's Tarceva for maintenance of NSCLC patients - PASS by FDA
GSK's Duodart for BPH - PASS by European regulatory clearance
Novartis' Joulferon (albinterferon alfa-2b) for chronic HCV - FAIL after EU feedback and Novartis pulls MAA.
Cell Therapeutics Pixuvri for treatment refractory NHL - INCOMPLETE by FDA and more clinical data needed
Merck Serono's Erbitux for 1st-line treatment of colorectal cancer - PASS by Japanese regulators.
Posted by Bruce Lehr April 23rd 2010.